**S3 File**

**RESULTS**

**Mass spectrometry demonstrates no differences in lipid mediators in BAL fluid**

Two BAL fluid samples in the pioglitazone cohort and one in the placebo cohort could not be analyzed by mass spectrometry as a result of storage issues. The volunteer in the placebo cohort who did not undergo the BAL procedure had no BAL sample to analyze. Therefore, the following numbers of samples were processed for LTB4 and LTE4: N=4 pioglitazone, N=6 zileuton, and N=4 placebo cohort. These results showed no differences in levels among the cohorts after normalizing for the epithelial cell lining fluid based on a one-way analysis of variance (see Table below for summary data, p = 0.55 for LTB4, p = 0.15 for LTE4). Given the negative results using the primary outcome measure, *K*i, limited mass spectrometry testing of four samples taken from the pioglitazone cohort and two samples from the zileuton cohort was performed for 5-HETE, 15-HETE, and LXA4. These measurements showed low levels; therefore, no additional correction for epithelial cell lining fluid was applied, and no statistical testing was performed. These data are included in the data file supplement for this manuscript.

|  |  |  |
| --- | --- | --- |
| **Treatment Cohort** | **LTB4** | **LTE4** |
| Placebo | 0.099±0.046 | 0.73±0.73 |
| Pioglitazone | 0.11±0.10 | 0.32±0.34 |
| Zileuton | 0.064±0.027 | 0.16±0.13 |